Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

Fig. 4

SCD1 activates EGFR/PI3K/Akt signaling and EMT phenotype of lung cancer cells. After treatment with Gefitinib (20 μM) and A939572 (1 nM), a, b the phosphorylation of EGFR/PI3K/AKT signaling pathway and the expression of caspase-3 were determined by western blotting. The expression of E-cadherin and N-cadherin was analyzed by western blotting (c, d) an immunofluorescence (e, f)

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us